What is the potency of hydrocortisone (corticosteroid) 2.5%?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Hydrocortisone 2.5% Potency Classification

Hydrocortisone 2.5% is classified as a mild potency topical corticosteroid. 1

Potency Classification

The standard classification system for topical corticosteroids places hydrocortisone in the mild (Class VII) category, with the range of 0.1-2.5% all falling within this lowest potency tier. 1 This classification is based on vasoconstrictor assays and clinical efficacy data that demonstrate hydrocortisone's relatively weak anti-inflammatory effects compared to other topical corticosteroids.

Clinical Context

  • Hydrocortisone 1% is the most commonly referenced concentration in the mild potency category, with the 2.5% formulation representing the upper end of this range but still maintaining mild potency status. 1

  • The potency hierarchy places hydrocortisone (mild) well below moderate potency agents like clobetasone butyrate 0.05% (Eumovate), potent agents like betamethasone valerate 0.1% (Betnovate), and very potent agents like clobetasol propionate 0.05% (Dermovate). 1

Important Caveats

  • Even mild potency corticosteroids can cause complications with chronic, uninterrupted use, including rosacea-like eruptions, perioral dermatitis, atrophy, and telangiectasia, particularly in vulnerable areas like the eyelids. 2

  • Therapy should be intermittent rather than continuous, even with mild potency agents, to minimize the risk of local adverse effects. 2

  • The 2.5% concentration does not elevate hydrocortisone to moderate potency—it remains in the mild category despite being at the higher end of the concentration range for this molecule. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Complications of topical hydrocortisone.

Journal of the American Academy of Dermatology, 1981

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.